GC Cell Corp
KOSDAQ:144510
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GC Cell Corp
Accrued Liabilities
GC Cell Corp
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GC Cell Corp
KOSDAQ:144510
|
Accrued Liabilities
₩12B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accrued Liabilities
₩191.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accrued Liabilities
₩52.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accrued Liabilities
₩449.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accrued Liabilities
₩375m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
18%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accrued Liabilities
₩462.2m
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
GC Cell Corp
Glance View
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2016-06-23. The firm operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.
See Also
What is GC Cell Corp's Accrued Liabilities?
Accrued Liabilities
12B
KRW
Based on the financial report for Dec 31, 2025, GC Cell Corp's Accrued Liabilities amounts to 12B KRW.
What is GC Cell Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
3%
Over the last year, the Accrued Liabilities growth was -23%. The average annual Accrued Liabilities growth rates for GC Cell Corp have been -13% over the past three years , 3% over the past five years .
